Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;46(3):481-501.
doi: 10.1007/s13402-023-00770-4. Epub 2023 Jan 23.

Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression

Affiliations
Review

Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression

Michelle de-Souza-Ferreira et al. Cell Oncol (Dordr). 2023 Jun.

Abstract

Background: Changes in protein glycosylation are widely observed in tumor cells. N-glycan branching through adding β1,6-linked N-acetylglucosamine (β1,6-GlcNAc) to an α1,6-linked mannose, which is catalyzed by the N-acetylglucosaminyltransferase V (MGAT5 or GnT-V), is one of the most frequently observed tumor-associated glycan structure formed. Increased levels of this branching structure play a pro-tumoral role in various ways, for example, through the stabilization of growth factor receptors, the destabilization of intercellular adhesion, or the acquisition of a migratory phenotype.

Conclusion: In this review, we provide an updated and comprehensive summary of the physiological and pathophysiological roles of MGAT5 and β1,6-GlcNAc branched N-glycans, including their regulatory mechanisms. Specific emphasis is given to the role of MGAT5 and β1,6-GlcNAc branched N-glycans in cellular mechanisms that contribute to the development and progression of solid tumors. We also provide insight into possible future clinical implications, such as the use of MGAT5 as a prognostic biomarker.

Keywords: Biomarker; Cancer; MGAT5; N-glycans.

PubMed Disclaimer

Similar articles

Cited by

References

    1. R.A. Flynn, K. Pedram, S.A. Malaker, P.J. Batista, B.A.H. Smith, A.G. Johnson, B.M. George, K. Majzoub, P.W. Villalta, J.E. Carette, C.R. Bertozzi, Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell 184, 3109-3124.e3122 (2021) - PubMed - PMC - DOI
    1. G.A. Khoury, R.C. Baliban, C.A. Floudas, Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci. Rep 1, 90 (2011) - PubMed - PMC - DOI
    1. A. Varki, R.D. Cummings, J.D. Esko, P. Stanley, G.W. Hart, M. Aebi, D. Mohnen, T. Kinoshita, N.H. Packer, J.H. Prestegard, R.L. Schnaar, P.H. Seeberger, Essentials of glycobiology, 4th edn. (Cold Spring Harbor, New York, 2022), pp. 103–115
    1. R.D. Cummings, I.S. Trowbridge, S. Kornfeld, A mouse lymphoma cell line resistant to the leukoagglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta 1,6 N-acetylglucosaminyltransferase. J. Biol. Chem 257, 13421–13427 (1982) - PubMed - DOI
    1. Y. Lu, W. Chaney, Induction of N-acetylglucosaminyltransferase V by elevated expression of activated or proto-Ha-ras oncogenes. Mol. Cell. Biochem 122, 85–92 (1993) - PubMed - DOI

LinkOut - more resources